These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15127378)

  • 21. [Autonomic function and severity of hypertrophic cardiomyopathy by power spectrum analysis on heart rate variability].
    Inoue S; Nezuo S; Sawayama T; Hasegawa K; Tamura K; Tanaka J; Nakamura T; Kato T; Ebata J
    Kokyu To Junkan; 1992 Dec; 40(12):1209-13. PubMed ID: 1480833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Syncope in hypertrophic cardiomyopathy: multivariate analysis of prognostic determinants.
    Nienaber CA; Hiller S; Spielmann RP; Geiger M; Kuck KH
    J Am Coll Cardiol; 1990 Apr; 15(5):948-55. PubMed ID: 2312980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abrupt aggravation of atrioventricular block and syncope in hypertrophic cardiomyopathy.
    Tamura M; Harada K; Ito T; Enoki M; Takada G
    Arch Dis Child; 1995 Dec; 73(6):536-7. PubMed ID: 8546514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. QT variability before and after episodes of nonsustained ventricular tachycardia in patients with hypertrophic cardiomyopathy.
    Mezilis NE; Parthenakis FI; Kanakaraki MK; Kanoupakis EM; Vardas PE
    Pacing Clin Electrophysiol; 1998 Nov; 21(11 Pt 2):2387-91. PubMed ID: 9825353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spatial QT Dispersion Predicts Nonsustained Ventricular Tachycardia and Correlates with Confined Systodiastolic Dysfunction in Hypertrophic Cardiomyopathy.
    Magrì D; Piccirillo G; Ricotta A; De Cecco CN; Mastromarino V; Serdoz A; Muscogiuri G; Gregori M; Casenghi M; Cauti FM; Oliviero G; Musumeci MB; Maruotti A; Autore C
    Cardiology; 2015; 131(2):122-9. PubMed ID: 25925893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. QT-interval abnormalities in hypertrophic cardiomyopathy.
    Dritsas A; Sbarouni E; Gilligan D; Nihoyannopoulos P; Oakley CM
    Clin Cardiol; 1992 Oct; 15(10):739-42. PubMed ID: 1395184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The value of time and frequency domain, and spectral temporal mapping analysis of the signal-averaged electrocardiogram in identification of patients with hypertrophic cardiomyopathy at increased risk of sudden death.
    Kulakowski P; Counihan PJ; Camm AJ; McKenna WJ
    Eur Heart J; 1993 Jul; 14(7):941-50. PubMed ID: 8375420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings.
    Fananapazir L; Chang AC; Epstein SE; McAreavey D
    Circulation; 1992 Sep; 86(3):730-40. PubMed ID: 1516184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained arrhythmias in hypertrophic obstructive cardiomyopathy.
    Kowey PR; Eisenberg R; Engel TR
    N Engl J Med; 1984 Jun; 310(24):1566-9. PubMed ID: 6539421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiparametric electrocardiographic evaluation of left ventricular hypertrophy in idiopathic and hypertensive cardiomyopathy.
    Lazzeri C; Barletta G; Badia T; Capalbio A; Del Bene R; Franchi F; Gensini GF; Michelucci A
    Ital Heart J; 2005 Apr; 6(4):304-10. PubMed ID: 15902928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the autonomic function in patients with hypertrophic cardiomyopathy with and without syncope.
    Macatrão-Costa MF; Arteaga-Fernandez E; de Brito FS; Darrieux F; de Melo SL; Scanavacca M; Sosa E; Hachul D
    Arq Bras Cardiol; 2013 Feb; 100(2):180-6. PubMed ID: 23503828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of the relationship between the ambulatory electrocardiography-based micro T-wave alternans and the predicted risk score of sudden cardiac death at 5 years in patients with hypertrophic cardiomyopathy.
    Özyılmaz S; Püşüroğlu H
    Anatol J Cardiol; 2018 Sep; 20(3):165-173. PubMed ID: 30152798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. QT prolongation and sudden cardiac death risk in hypertrophic cardiomyopathy.
    Patel SI; Ackerman MJ; Shamoun FE; Geske JB; Ommen SR; Love WT; Cha SS; Bos JM; Lester SJ
    Acta Cardiol; 2019 Feb; 74(1):53-58. PubMed ID: 29513133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of heart rate variability in hypertrophic cardiomyopathy. Association with clinical and prognostic features.
    Counihan PJ; Fei L; Bashir Y; Farrell TG; Haywood GA; McKenna WJ
    Circulation; 1993 Oct; 88(4 Pt 1):1682-90. PubMed ID: 8403313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can the assessment of dynamic QT dispersion on exercise electrocardiogram predict sudden cardiac death in hypertrophic cardiomyopathy?
    Yi G; Poloniecki J; Dickie S; Elliott PM; Malik M; McKenna WJ
    Pacing Clin Electrophysiol; 2000 Nov; 23(11 Pt 2):1953-6. PubMed ID: 11139965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship of mechanical dyssynchrony to QT interval prolongation in hypertrophic cardiomyopathy.
    Badran HM; Elnoamany MF; Soltan G; Ezat M; Elsedi M; Abdelfatah RA; Yacoub M
    Eur Heart J Cardiovasc Imaging; 2012 May; 13(5):423-32. PubMed ID: 22185753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. QT-interval variability and autonomic control in hypertensive subjects with left ventricular hypertrophy.
    Piccirillo G; Germanò G; Quaglione R; Nocco M; Lintas F; Lionetti M; Moisè A; Ragazzo M; Marigliano V; Cacciafesta M
    Clin Sci (Lond); 2002 Mar; 102(3):363-71. PubMed ID: 11869178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy.
    Gawor M; Śpiewak M; Janas J; Kożuch K; Wróbel A; Mazurkiewicz Ł; Baranowski R; Marczak M; Grzybowski J
    Kardiol Pol; 2017; 75(10):997-1004. PubMed ID: 28612913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolongation of the QTc interval predicts appropriate implantable cardioverter-defibrillator therapies in hypertrophic cardiomyopathy.
    Gray B; Ingles J; Medi C; Semsarian C
    JACC Heart Fail; 2013 Apr; 1(2):149-55. PubMed ID: 24621839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The value of exercise test, Holter monitoring, and programmed electrical stimulation in detection of ventricular arrhythmias in patients with hypertrophic cardiomyopathy.
    Jansson K; Dahlström U; Karlsson E; Nylander E; Walfridsson H; Sonnhag C
    Pacing Clin Electrophysiol; 1990 Oct; 13(10):1261-7. PubMed ID: 1701541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.